Clinicopathologic characteristics of HER2-positive metaplastic squamous cell carcinoma of the breast
| Autor: | Bing Wei, Zhang Zhang, Hong Bu, Ting Lei, Jieliang Yang, Mengjia Shen, Libo Yang, Yingying Fan, Tianjie Pu, Yu Zhang, Min Chen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Adult medicine.medical_specialty Poor prognosis China Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Aggressive disease Disease-Free Survival Pathology and Forensic Medicine Targeted therapy 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine mental disorders medicine Humans Breast skin and connective tissue diseases neoplasms Survival analysis In Situ Hybridization Fluorescence Aged business.industry Human epidermal growth factor Critical factors General Medicine Middle Aged medicine.disease Prognosis Immunohistochemistry 030104 developmental biology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Metaplastic squamous cell carcinoma business |
| Zdroj: | Journal of clinical pathology. 75(1) |
| ISSN: | 1472-4146 |
| Popis: | AimsThe aim of this study was to analyse the clinicopathological features and prognosis of human epidermal growth factor receptor-2 (HER2)-positive metaplastic squamous cell carcinoma (MSCC).MethodsFifty-eight patients with MSCC of the breast who were classified into 45 triple-negative and 13 HER2-positive subgroups diagnosed at the West China Hospital, Sichuan University, from 2004 to 2018, were enrolled. Clinicopathological features were collected and compared between HER2-positive MSCC, triple-negative MSCC, HER2-positive invasive breast carcinoma of no special type (NST) and triple-negative NST groups. In the prognostic survival analysis, HER2-positive MSCCs was compared with triple-negative MSCCs, HER2-positive NSTs and triple-negative NSTs.ResultsCompared with triple-negative MSCCs, more patients with Ki-67 low expression were in HER2-positive MSCCs (pConclusionIn conclusion, our study indicates that HER2-positive MSCC is an aggressive disease with unique clinicopathological characteristics. Both HER2-positive status and an SCC component are critical factors for poor prognosis. HER2-positive MSCC and triple-negative MSCC are distinct subgroups. Corresponding targeted therapy recommendations should be made for this HER2-positive MSCC group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|